Tony Soprano's wardrobe up for sale & other: August 2008

Friday, 22 August 2008

Weinstein Co. makes int'l sales chief decision

Michael Rothstein, Jonathan Kier will run division

NEW YORK -- After weeks of speculation all over who would replace of late departed Weinstein Co. external sales president Glen Basner, the answer arrived Thursday: no one.

Instead, the company has promoted Michael Rothstein to executive vp international sales and statistical distribution and Jonathan Kier to senior vp international gross revenue and statistical distribution. The geminate will run the division and report to COO Lee Solomon, as Basner did ahead them before departing Aug. 1.

International gross revenue has been one of the Weinstein Co.'s few consistent areas of profits since Basner built the department from scratch trio years ago, recently presenting a strong Cannes securities industry sales slate with many nonstudio titles. The eXEC is expected to ground at some other sales operation soon.

A spokesperson said there ar no plans to name a new president, and that Solomon will continue to superintend the arm as he has since becoming Weinstein Co.'s low COO in February.

Former senior vp Rothstein has worked with the Weinsteins since 1997 at Miramax, and as with former vp Kier joined Weinstein Co. when it was founded three years ago. Kier arrived from the affiliate sales strategy group at MTV Networks. Both will work from the outfit's New York office as they preparation a slate for the American Film Market.

More info

Tuesday, 12 August 2008

Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial Of Its Oral Insulin Capsule

�Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral delivery systems, announced successful results from the clinical visitation of its oral insulin capsule, ORMD 0801. The trial demonstrated that the product had a beneficial safety profile and well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes.

The study was conducted at Hadassah University Medical Center in Jerusalem and was a continuation of the successful Phase 1B trials that Oramed completed earlier this year.

This trial was the first to expose patients with type 2 diabetes to ORMD 0801 and its primary goals were to assess the safety, tolerability and pharmcodynamic effects in these patients.

ORMD 0801 was well tolerated by all patients and had a good safety profile; no good adverse events were encountered throughout the study. In 6 of the 9 subjects analyzed, statistically significant reductions in glucose as well as C-peptide were observed.

"We are pleased with the results from the Phase 2A test as they show that ORMD 0801 was effective and there were no safety issues," said Oramed's Chief Scientist, Dr. Miriam Kidron. "We look forrad to our next stage of examination and taking the succeeding steps towards making an oral insulin capsule a reality for millions of diabetics close to the worldly concern."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines soon delivered via injection. Oramed is seeking to revolutionize the handling of diabetes through its patented flagship product, an orally ingestible insulin ejector seat currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit hTTP://www.oramed.com

Forward-looking statements

Some of the statements contained in this press out release ar forward-looking statements which involve known and unknown risks, uncertainties and other factors which crataegus oxycantha cause the actual results, performance or achievements of the company, or industriousness results, to be materially different from any next results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to to the progress, timing, cost, and results of clinical trials and ware development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from early pharmaceutical or biotechnology companies; and the company's ability to incur additional financial support required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause literal results, carrying out or achievements of the company to differ materially from those expressed or implied in such forth looking statements. The company undertakes no obligation to update or revise whatever forward-looking statements.

Oramed Pharmaceuticals

More information

Wednesday, 6 August 2008

Los Secretos

Artist: Los Secretos

   Genre(s):
Other

Discography:

Grandes Exitos Vol. II

Year: 1999
Tracks: 20

Known as one of the major acts of the Apostles of the Spanish New Wave, los Secretos was formed in 1980 by brothers Javier, Enrique, and Alvaro Urquijo, wHO where joined by a irregular drummer. After three active age, the quartette became a duet in 1983, with Alvaro and Enrique Urquijo playacting their have got pop/rock tunes. Later, drummer Steve Jordan, bassist Nacho Lles, and guitar role player RamÃ³n Arroyo linked the act, reversive as a grouping with the discharge of El Primer Cruce and an album called ContinuarÃ¡. In 1988, later on they were joined by keyboardist JesÃºs Redondo, the band issued a live record, called Directo, the low one to attain gold position. Los Secretos disbanded by the end of the nineties. Soon after, the group's members got involved in unlike projects.